Jay D. Kranzler, M.D., Ph.D. – Cypress Bioscience, Inc.
Chairman of the Board, Chief Executive Officer

See Management Team for Biography

Roger L. Hawley

Roger L. Hawley, age 54, has served as a director since April 26, 2007. Since February 2006, Mr. Hawley has served as chief executive officer and a director of Zogenix, Inc., a privately-held specialty pharmaceutical company. From 2003 until January 2006, Mr. Hawley served as executive vice president, commercial and technical operations of InterMune, Inc, a publicly-held biopharmaceutical company. From 2002 to 2003, Mr. Hawley served as chief commercial officer at Prometheus Laboratories, Inc., a specialty pharmaceutical company. From 2001 to 2002, Mr. Hawley served as vice president/general manager of sales and marketing at Elan Pharmaceuticals, Inc., a publicly-held biopharmaceutical company. From 1987 to 2001, Mr. Hawley held various management positions in corporate finance, sales, and marketing at GlaxoSmithKline, Inc. Prior to joining GlaxoSmithKline, Mr. Hawley spent 12 years in financial management with Marathon Oil Company. Mr. Hawley also serves as a director of Targeted Genetics Corporation, a publicly-traded clinical-stage biotechnology company, and Alios BioPharma Inc., a privately-held biotechnology company. Mr. Hawley holds a B.S. in accounting from Eastern Illinois University.

Amir Kalali, M.D.

Dr. Kalali is currently Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS, at Quintiles Inc., focusing on developing novel compounds for the treatment of disorders of the central nervous system. He is globally responsible for the medical and scientific aspects of development programs in psychiatry and neurology. He is also Professor of Psychiatry at University of California San Diego.  He was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), and currently the Executive Secretary.  Dr. Kalali received his M.D. from the University of London, United Kingdom.  He completed his psychiatry training at University College and Middlesex School of Medicine, London University. Dr. Kalali has been an academic investigator in over 70 psychopharmacological clinical trials and at Quintiles has had medical and scientific responsibility for over 150 clinical trials.  Dr. Kalali regularly presents at national and international scientific meetings, and lectures frequently on psychopharmacological and drug development topics. Dr. Kalali is the Editor of the journal Psychiatry, and is on the editorial board of several other journals. He has published widely in journals such as the Archives of General Psychiatry, The American Journal of Psychiatry, and the British Journal of Psychiatry.  Dr. Kalali is an active member of the Scientific Advisory Boards of many pharmaceutical companies and sits on the Board of Directors of the Neuroscience Education Institute and Tikvah Therapeutics.In 2005 and 2006 PharmaVOICE magazine named Dr. Kalali as one its 100 most inspiring leaders in the life sciences.

Jon W. McGarity
Jon W. McGarity has served as a director since March 2004. Mr. McGarity is the President and Chief Executive Officer of EthiX Associates, which he founded in 1996 and which is a company that provides executive consulting services in pharmaceutical/biotech/healthcare business planning, strategy and development. Prior to establishing EthiX Associates, Mr. McGarity was the Vice Chairman, President and Chief Operating Officer of Pharmaceutical Marketing Services, Inc., which provided marketing and information services to the global pharmaceutical/healthcare industry. Mr. McGarity is a member of the board of the Global Advisory Council at Thunderbird, The Garvin School of International Management, Chairman of the Board of Directors of the Arizona BioIndustry Association and serves on the Board of Directors of the Arizona Technology Council, the Masters Level Computational Biosciences Degree Program and the Technopolis Program at Arizona State University.  Mr. McGarity also serves on the Board of Directors of two private biotechnology companies, Ribomed Biotechnologies, Inc. and Cynexus Corporation.

Jean-Pierre Millon
Jean-Pierre Millon is lead director at Cypress Bioscience [NASDAQ: CYPB] and a director at CVS Caremark [NYSE:CVS], Medical Present Value, a private medical administration company, and Prometheus Labs, a specialty pharmaceutical company. He is a co-founder of BLS LLC, a consulting and investing entity based in Indianapolis. He recently joined the board of HAPC, a special-purpose acquisition company. He was a special limited partner at Care Capital LLC, a HealthCare Venture Fund, from 2001 until 2003.  Mr. Millon’s board position at Caremark evolved as a result of Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Mr. Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Mr. Millon was president and chief executive officer of PCS from 1996 to 2000.

Prior to joining PCS, Mr. Millon was an executive with Eli Lilly and Company, PCS’ former parent company. Mr. Millon’s career with Lilly and its subsidiaries spanned two decades and was highlighted by leadership positions in the United States and executive posts in the Orient, Europe and the Caribbean Basin.

Mr. Millon served as president and general manager of Lilly Japan K.K. and vice president of the Lilly pharmaceutical division in Kobe, Japan.

Before transferring to Japan, Mr. Millon directed strategic planning, personnel, Japan business planning and marketing research efforts at Lilly headquarters in Indianapolis. Prior to those corporate directorships, Mr. Millon served as general manager of the Caribbean Basin in Puerto Rico. He also served in financial leadership roles in West Germany, Belgium and France.

He earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University in Evanston, Ill.

A native of Paris, Mr. Millon is fluent in French, English, German and Spanish. He has a strong interest in civic and business organizations. He is a trustee of the Barrow Foundation, a leading neurological institution in Phoenix. He is a member of the Kellogg Graduate School of Management Alumni Advisory Board.

Mr. Millon shares his time between Phoenix Ariz. and La Jolla, Calif.

Perry B. Molinoff, M.D.
Dr. Molinoff, a neuropharmacologist with an M.D. from Harvard, and since November 2003 has been the Vice Provost for Research at the University of Pennsylvania. He holds a faculty position in the Department of Pharmacology and was the A.N. Richards Professor of Pharmacology at the University of Pennsylvania. He is also an Adjunct Professor of Physiology and Neuroscience at the Medical University of South Carolina, Charleston, SC. In addition to his faculty appointments from January 1995 until March 2001, Dr. Molinoff was the Vice President - Neuroscience and Genitourinary Drug Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, where he was responsible for implementing and directing the Institute's research efforts in multiple therapeutic areas. He established a multidisciplinary structure to facilitate rapid development of drugs directed against a variety of therapeutic targets across a broad spectrum of neurologic, psychiatric and genitourinary diseases, including stroke, depression, sleep disorders, obesity, Alzheimer's disease, analgesia and neuropathic pain, urinary incontinence and erectile dysfunction. From September 2001 until November 2003, Dr. Molinoff served as Executive Vice President of Research and Development at Palatin Technologies, Edison, NJ, where he was responsible for all basic, preclinical and clinical research. Programs included the recently approved NeuroSpect for imaging infection including equivocal appendicitis and PT-141, a melanocortin agonist being developed for the treatment of sexual dysfunction. Dr. Molinoff has been a member of the Board of Directors of Palatin Technologies since November 2001. He is a member of multiple editorial advisory boards for scientific and educational journals and has authored or edited 6 books including Basic Neurochemistry and Goodman and Gilman's text, The Pharmacological Basis of Therapeutics, as well as over 225 manuscripts.

Tina S. Nova

Tina S. Nova, Ph.D., age 53, has served as a director since April 26, 2007. Dr. Nova is a co-founder of Genoptix, Inc., a provider of personalized medicine services, and has served as its President and Chief Executive Officer and as a member of its board of directors since March 2000. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, where she served as Chief Operating Officer and President from 1994 to January 2000. From 1992 to 1994, Dr. Nova served as Chief Operating Officer of Selective Genetics, a targeted therapy, biotechnology company. From 1988 to 1992, Dr. Nova held various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, most recently serving as Executive Director of New Leads Discovery. Dr. Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Dr. Nova is the life science sector representative to the Independent Citizen's Oversight Committee overseeing the implementation of the California stem cell initiative, Proposition 71. Dr. Nova also serves on the board of directors of Arena Pharmaceuticals, Inc., a publicly traded clinical-stage biopharmaceutical company. Dr. Nova holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.

Daniel H. Petree
Daniel H. Petree has served as a director since June 2004. Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life sciences companies, which he co-founded in 2000. From 1998 to 1999, Mr. Petree was the President and Chief Operating Officer of Axys Pharmaceuticals, a structure-based drug design company based in South San Francisco. From 1993 to 1998, he also held successive positions at Axys (and its predecessor, Arris Pharmaceuticals) as Executive Vice President of Business Development and Chief Financial Officer. From 1992 to 1993, Mr. Petree was Vice President of Business Development at TSI Corporation, a clinical research organization in Worcester, MA. Mr. Petree's operating management experience was preceded by five years in investment banking at Montgomery Securities. He also practiced as a corporate and securities lawyer with Heller, Ehrman, White & McAuliffe in Palo Alto, CA.